Is Bristol-Myers Squibb Co. a growth stock? A data-driven read on its earnings momentum, price leadership, and demand, scored against every US stock from SEC filings and daily prices, and re-ranked after every close.
Partly. BMY is a mixed caseAs of the 2026-07-27 close, BMY scores 69 out of 99 on our growth-stock rating, a mixed growth-stock profile. That ranks it 485th of 4,897 rated US stocks, the top 10% of the market.
Its strongest trait is C (current quarterly earnings) at 99, and its weakest is S (supply & demand) at 22. BMY clears 3 of the six core growth traits we score per stock; the seventh, overall market direction, is judged market-wide.
On price, BMY carries a middling Relative Strength rating of 73, meaning it has outperformed about 73% of the market over the past year.
Underneath the score: quarterly earnings up 9% year over year, sales up 3%, trading at a fresh 52-week high.
The six traits that separate real growth stocks from the rest: earnings, price leadership, and demand. Each is scored 1–99 against the whole US market. We compute them with the CANSLIM method, double-weighting earnings and relative strength.
| C | Current quarterly earnings most recent EPS growth vs. a year ago |
99 |
| A | Annual earnings growth multi-year earnings trend |
47 |
| N | New highs & catalysts proximity to new 52-week highs |
90 |
| S | Supply & demand volume behind the move vs. share supply |
22 |
| L | Leader or laggard Relative Strength within its group |
55 |
| I | Institutional sponsorship fund accumulation and 13F ownership |
61 |
BMY passes some CANSLIM traits but not others. The letter breakdown above shows exactly where it holds up and where it falls short.
The stocks ranking above BMY today, the growth leaders you’d weigh against it.
Where BMY sits in its base, its 52-week path, and the trait trend over the past year.
Every US stock scored on the traits that define a growth stock and re-ranked after each close, with the top ranks, the full trait breakdown, and today’s market read.
Open the app, free through September 1Partly. BMY is a mixed case. BMY passes some CANSLIM traits but not others. The letter breakdown above shows exactly where it holds up and where it falls short.
Bristol-Myers Squibb Co. (BMY) scores 69 out of 99 on our growth-stock rating as of the 2026-07-27 close, ranking 485th of 4,897 rated US stocks.
BMY's most recent quarterly earnings were up about 9% year over year, with sales up 3%.
BMY has a Relative Strength rating of 73, meaning it has outperformed roughly 73% of the US market over the trailing year.
Create a free Growth Stock Analyzer account to see where BMY ranks against every US stock, the stronger growth stocks to weigh against it, and its full price and earnings history.
Want the method behind the score? Read how we grade growth stocks with CANSLIM.